An example is provided by Nanjing Biolegend with its anti-BCMA CAR T cell for multiple myeloma, now approved by FDA and promising data from early phase clinical trials with anti-claudin CAR T cells in gastrointestinal malignancies (4, 18, 71). This evidence concerns the gene TNFRSF17 and AL amyloidosis.